Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers

Background: Protease activated receptor-2 (PAR-2) is a transmembrane G protein coupled receptor preferentially activated by trypsin and tryptase. The protease activated receptors play an important role in most components of injury responses including cell proliferation, migration, matrix remodelling, and inflammation. Cigarette smoking causes an inflammatory process in the central airways, peripheral airways, lung parenchyma, and adventitia of pulmonary arteries. Methods: To quantify the expression of PAR-2 in the central airways of smokers and non-smokers, surgical specimens obtained from 30 subjects undergoing lung resection for localised pulmonary lesions (24 with a history of cigarette smoking and six non-smoking control subjects) were examined. Central airways were immunostained with an antiserum specific for PAR-2 and PAR-2 expression was quantified using light microscopy and image analysis. Results: PAR-2 expression was found in bronchial smooth muscle, epithelium, glands, and in the endothelium and smooth muscle of bronchial vessels. PAR-2 expression was similar in the central airways of smokers and non-smokers. When smokers were divided according to the presence of symptoms of chronic bronchitis and chronic airflow limitation, PAR-2 expression was increased in smooth muscle (median 3.8 (interquartile range 2.9–5.8) and 1.4 (1.07–3.4) respectively); glands (33.3 (18.2–43.8) and 16.2 (11.5–22.2), respectively); and bronchial vessels (54.2 (48.7–56.8) and 40.0 (36–40.4), respectively) of smokers with symptoms of chronic bronchitis with normal lung function compared with smokers with chronic airflow limitation (COPD), but the increase was statistically significant (p<0.005) only for bronchial vessels. Conclusions: PAR-2 is present in bronchial smooth muscle, glands, and bronchial vessels of both smokers and non-smokers. An increased expression of PAR-2 was found in bronchial vessels of patients with bronchitis compared with those with COPD.

[1]  R. Marthan,et al.  Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. , 2001, Journal of applied physiology.

[2]  M. Hollenberg,et al.  Airway epithelial cells release eosinophil survival-promoting factors (GM-CSF) after stimulation of proteinase-activated receptor 2. , 2001, The Journal of allergy and clinical immunology.

[3]  M. Saetta,et al.  Structural basis for airflow limitation in chronic obstructive pulmonary disease. , 2000, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[4]  J. Wallace,et al.  Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. , 2000, The Journal of allergy and clinical immunology.

[5]  A. Kawabata,et al.  Activation of protease-activated receptor-2 (PAR-2) triggers mucin secretion in the rat sublingual gland. , 2000, Biochemical and biophysical research communications.

[6]  J. Moffatt,et al.  Protease-activated receptors: sentries for inflammation? , 2000, Trends in pharmacological sciences.

[7]  J. Wallace,et al.  Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism , 2000, Nature Medicine.

[8]  G. Stewart,et al.  Modulation of airway smooth muscle tone by protease activated receptor‐1,‐2,‐3 and ‐4 in trachea isolated from influenza A virus‐infected mice , 2000, British journal of pharmacology.

[9]  M. D'Andrea,et al.  Localization of Protease-Activated Receptors -1 and -2 in Human Mast Cells: Indications for an Amplified Mast Cell Degranulation Cascade , 2000, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[10]  M. Hollenberg,et al.  Proteinase-activated receptor 2 (PAR(2)): development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)- and PAR(2)-derived peptide ligands. , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  M. Hollenberg.  Protease-activated receptors: PAR4 and counting: how long is the course? , 1999, Trends in pharmacological sciences.

[12]  J. Wallace,et al.  Characterization of the inflammatory response to proteinase‐activated receptor‐2 (PAR2)‐activating peptides in the rat paw , 1999, British journal of pharmacology.

[13]  V. Peinado,et al.  Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[14]  M. D'Andrea,et al.  Increased Expression of Protease Activated Receptor-2 (PAR-2) in Balloon-Injured Rat Carotid Artery , 1999, Thrombosis and Haemostasis.

[15]  M. Carr,et al.  A protective role for protease-activated receptors in the airways , 1999, Nature.

[16]  M. Steinhoff,et al.  Trypsin activates pancreatic duct epithelial cell ion channels through proteinase-activated receptor-2. , 1999, The Journal of clinical investigation.

[17]  T. Minami,et al.  Increased vascular permeability by a specific agonist of protease‐activated receptor‐2 in rat hindpaw , 1998, British journal of pharmacology.

[18]  S. Holgate,et al.  The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. , 1998, Journal of immunology.

[19]  M. Steinhoff,et al.  Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. , 1998, American journal of physiology. Cell physiology.

[20]  S. M. Baker,et al.  Characterization of Protease-activated Receptor-2 Immunoreactivity in Normal Human Tissues , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  M. Hollenberg,et al.  Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y. Miyagi,et al.  Expression of trypsin in vascular endothelial cells , 1997, FEBS letters.

[23]  Patricia Andrade-Gordon,et al.  Endothelial Cell Thrombin Receptors and PAR-2 , 1997, The Journal of Biological Chemistry.

[24]  H. Magazine,et al.  Protease activated receptors modulate aortic vascular tone. , 1996, International journal of cardiology.

[25]  Meeta Chatterjee,et al.  Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. , 1996, Circulation research.

[26]  S. Coughlin,et al.  Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. , 1996, The Biochemical journal.

[27]  M. Hollenberg,et al.  Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. , 1995, Canadian journal of physiology and pharmacology.

[28]  B. Strömbeck,et al.  Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. , 1995, European journal of biochemistry.

[29]  D. Olivieri,et al.  Mast cells in the airway lumen and bronchial mucosa of patients with chronic bronchitis. , 1994, American journal of respiratory and critical care medicine.

[30]  Lingzhi Fan,et al.  The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system , 1988, Neuroscience Letters.

[31]  D. Moir.  Medicine , 1894, The Indian medical gazette.

[32]  L. Fabbri,et al.  Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. , 2000, American journal of respiratory and critical care medicine.

[33]  M. Hollenberg,et al.  Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[34]  J. Kips,et al.  IL-4 and IL-5 mRNA in the bronchial wall of smokers , 1999, ATS 1999.

[35]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[36]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.